RPh201

Phase 2Small molecule

RRegenera Pharma Ltd

RPh201 is one of 97 small molecule programs targeting Anterior Ischemic Optic Neuropathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anterior Ischemic Optic NeuropathyActive, not recruiting

NeuropathyActive, not recruiting

Vascular DiseaseActive, not recruiting

Anterior Ischemic Optic NeuropathyPhase 2

Active, not recruiting

NeuropathyPhase 2

Active, not recruiting

Vascular DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Neuropathy

#DrugCompanyPhaseTrials

Asceniv

CSL Behring

Phase 3

1 2

Avandia

Alnylam Pharmaceuticals

Phase 3

1 3

Vimpat

UCB

Phase 3

1 4

Savella

AbbVie

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

3 6

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 7

Claritin

PPerrigo Company

Phase 3

1 8

Glutamine

Sanofi

Phase 3

2 9

Curcumin

Merck & Co.

Phase 3

1 10

Taxol

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuropathy1 trial

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

Completed·RRegenera Pharma Ltd·Phase 2·NCT02045212·22 enrolled

Chronic1 trial

The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study

Suspended·HHadassah Medical Organization·Phase 1·NCT01438684·10 enrolled

Anterior Ischemic Optic Neuropathy1 trial

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Terminated·RRegenera Pharma Ltd·Phase 2·NCT03547206·165 enrolled

Vascular Disease1 trial

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

Completed·RRegenera Pharma Ltd·Phase 2·NCT03462121·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RPh201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RPh201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RPh201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regenera Pharma Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRegenera Pharma Ltd

RPh201

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuropathy1 trial

Chronic1 trial

Anterior Ischemic Optic Neuropathy1 trial

Vascular Disease1 trial

References

Drug Info

Quick Facts

Related News